In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Guilford Pharmaceuticals gets $27.2mm from investors

Executive Summary

Guilford Pharmaceuticals (therapeutics for neurology and hospital markets) sold 4.8mm common shares at $5.67 each (a 15% discount to market), grossing $27.2mm, to Sage Capital, OrbiMed Advisors, Highbridge Capital, Domain Associates, UBS O'Connor LLC, Quogue Capital, and Merlin BioMed. The investors also received 7-year warrants to buy about 961.4k additional common shares at $7.55 each.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies